Tetrabenazine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Tetrabenazine
- Tetrabenazine: From Huntington’s Disease Chorea to Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)
Tetrabenazine: From Huntington’s Disease Chorea to Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)
One-Sentence Summary
Tetrabenazine is a VMAT2 (vesicular monoamine transporter 2) inhibitor internationally used to reduce chorea associated with Huntington’s disease. The TxGNN model predicts a possible association with Polycystic Kidney Disease 3, with or without Polycystic Liver Disease, but this candidate is currently supported by 0 clinical trials and 20 background publications that describe the disease itself rather than Tetrabenazine-specific evidence, placing it at the lowest evidence tier (L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this Evidence Pack (original_indications is empty); internationally used for Huntington’s disease-associated chorea, as referenced within the supporting trial evidence for this candidate |
| Predicted New Indication | Polycystic Kidney Disease 3, with or without Polycystic Liver Disease |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Structured mechanism-of-action data is not available in this Evidence Pack (original_moa: [Data Gap]). However, the accompanying rationale for this candidate notes that Tetrabenazine is a known VMAT2 inhibitor, which depletes presynaptic monoamine neurotransmitters (dopamine, serotonin, noradrenaline). This pharmacology underlies its established use in hyperkinetic movement disorders such as Huntington’s disease-associated chorea.
Polycystic kidney disease and polycystic liver disease, in contrast, are driven by an entirely different pathophysiological pathway — mutations in genes such as PKD1, PKD2, and PKHD1 leading to primary cilia dysfunction and progressive cyst formation in the kidney and liver. There is no established pharmacological or molecular link between central monoamine depletion and renal/hepatic cystogenesis.
Consistent with this, the Evidence Pack’s own mechanistic assessment for this candidate explicitly finds no plausible pathway connecting VMAT2 inhibition to ciliopathy-driven cyst formation. All 20 supporting literature items describe the natural history, genetics, diagnosis, or clinical management of polycystic kidney/liver disease itself — none mention Tetrabenazine or VMAT2 pathways. This pattern is consistent with disease-keyword co-occurrence noise in the underlying knowledge graph rather than a genuine drug-repurposing signal, and the same weak-evidence pattern (L4–L5, “Hold”) recurs across the other nine predicted indications for this candidate in the wider evidence set.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38958301 | 2024 | Guideline | Am J Gastroenterol | ACG clinical guideline on focal liver lesions, including management of polycystic liver disease |
| 35728731 | 2022 | Guideline | J Hepatol | EASL clinical practice guidelines on the management of cystic liver diseases |
| 30819518 | 2019 | Review | Lancet | Comprehensive review of ADPKD pathophysiology, genetics, and extrarenal manifestations |
| 35487607 | 2022 | Review | Clin Liver Dis | Review of the ADPKD/polycystic liver disease clinical course; notes tolvaptan (not Tetrabenazine) as an approved treatment |
| 29038287 | 2018 | Review | J Am Soc Nephrol | Genetic complexity and gene overlap between ADPKD and autosomal dominant polycystic liver disease |
| 38097330 | 2023 | Review | Adv Kidney Dis Health | Genetic spectrum of PKD1/PKD2 mutations and resulting phenotypes |
| 34724412 | 2022 | Review | Annu Rev Pathol | Mechanistic understanding and treatment advances in polycystic liver disease |
| 36200122 | 2022 | Review | Hepat Med | Overview of pathophysiology, diagnosis, and treatment of polycystic liver disease |
| 28375157 | 2017 | Basic Science | J Clin Invest | Whole-exome sequencing identifies effectors of polycystin-1 function in isolated polycystic liver disease |
| 37266470 | 2023 | Case Report | Maedica | Case report of ADPKD/adult polycystic liver disease associated with advanced gastric cancer |
Note: None of the above literature mentions Tetrabenazine, VMAT2, or any pharmacological intervention relevant to this drug. All items describe the natural history, genetics, or clinical management of polycystic kidney/liver disease itself.
UK Market Information
Tetrabenazine currently holds no marketing authorisation on record in this Evidence Pack (market status: Not Marketed; 0 licenses).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale:
- This candidate sits at evidence level L5 (model prediction only), with zero drug-specific clinical trials and literature limited entirely to disease background rather than Tetrabenazine-specific data. The Evidence Pack’s own mechanistic assessment finds no plausible pathway linking VMAT2 inhibition to renal/hepatic cystogenesis, and this lack of support is consistent across the broader set of predicted indications for this drug.
To proceed, the following is needed:
- MHRA/SmPC-sourced key warnings and contraindications (currently a Blocking data gap, DG001)
- Confirmed mechanism-of-action data via DrugBank (currently a High-severity data gap, DG002)
- Drug-specific preclinical or mechanistic studies linking the VMAT2 pathway to ciliopathy/cystogenesis, should this hypothesis be pursued further
- Clarification of Tetrabenazine’s current UK licensing/marketing status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.